Company intelligence / Profile preview

ImmunoVaccine Technologies Inc.

Halifax/Dartmouth, Nova Scotia, Canadaorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

The company developed immunotherapies for cancer and infectious diseases using its proprietary DPX platform technology. Its lead candidate maveropepimut-S was in Phase 2 for DLBCL and platinum-resistant ovarian cancer.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Therapeutic vaccinesSynthetic peptide vaccinesShared antigen vaccines
Industry: Biotech

Drug pipeline

1 asset

maveropepimut-S

Phase 2

Indications: Ovarian cancer, Non-small cell lung cancer

Partnerships

Immunotope Inc.

Beyond the preview

Go deeper on ImmunoVaccine Technologies Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoVaccine Technologies Inc..

Explore the full profile